Health Economics›Marginal zone lymphoma›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Marginal zone lymphoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	~39.4 mo	—	~35	~R 3 036 103 PFS proxy · indirect	5
Ibritumomab tiuxetan protocol Variant #18	—	R 27 524	8d	~36.5 mo	—	~139	~R 3 825 804 PFS proxy · indirect	1
PCR N/A - secondary systemic drug Partial	—	R 172	28d	—	—	—	—	—

3 of 3 regimens shown